Santiago G Lago, Jakub Tomasik, Geertje F van Rees, Marina Rubey, Emiliano Gonzalez-Vioque, Jordan M Ramsey, Frieder Haenisch, Jantine A Broek, Javier Vázquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Tillmann Ruland, Bonnie Auyeug, Olya Mikova, Nikolett Kabacs, Volker Arolt, Simon Baron-Cohen, Benedicto Crespo-Facorro, Sabine Bahn
Recent evidence suggests that comorbidities between neuropsychiatric conditions and metabolic syndrome may precede and even exacerbate long-term side-effects of psychiatric medication, such as a higher risk of type 2 diabetes and cardiovascular disease, which result in increased mortality. In the present study we compare the expression of key metabolic proteins, including the insulin receptor (CD220), glucose transporter 1 (GLUT-1) and fatty acid translocase (CD36), on peripheral blood mononuclear cell subtypes from patients across the neuropsychiatric spectrum, including schizophrenia, bipolar disorder, major depression and autism spectrum conditions (n=25/condition), relative to typical controls (n=100)...
September 5, 2020: Brain, Behavior, and Immunity